Loading ...
Sorry, an error occurred while loading the content.

Fw: NATAP: Latest Articles About Hepatitis C

Expand Messages
  • alleypat
    NATAP http://natap.org/ ... Latest articles about Hepatitis C. http://www.natap.org 1. VX-950 Phase 2b PROVE 1 Study Interim Safety & Antiviral Activity at
    Message 1 of 1 , Dec 27, 2006
    View Source
    • 0 Attachment
      NATAP http://natap.org/
      _______________________________________________



      --------------------------------------------------------------------------------


      Latest articles about Hepatitis C.
      http://www.natap.org


      1. VX-950 Phase 2b PROVE 1 Study Interim Safety & Antiviral Activity at Week 12 - (12/20/06)

      2. New HCV Drug Celgosivir/MX-3253, oral alpha-glucosidase I inhibitor - (12/20/06)

      3. Vertex Pharmaceuticals Announces Results of First Interim Safety and Antiviral Analysis of the PROVE 1 Clinical Trial of Investigational HCV Protease Inhibitor Telaprevir (VX-950) - (12/20/06)

      4. Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) in Combination With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C - (12/20/06)

      5. Pevion Biotech Announces Its Hepatitis C Therapeutic Vaccine Enters Clinical Phase I - (12/20/06)

      6. InterMune Initiates Phase 1a Clinical Trial Evaluating Hepatitis C Protease Inhibitor ITMN-191 in Collaboration with Roche - (12/20/06)

      7. InterMune Initiates Phase 1a Clinical Trial Evaluating Hepatitis C Protease Inhibitor ITMN-191 in Collaboration with Roche - (12/20/06)

      8. Procrit/EP- Safety Alert from FDA - (12/18/06)

      9. Epoetin Alfa and Risk for Complications - (12/18/06)

      10. Correction of Anemia - Payoffs and Problems EDITORIAL - (12/18/06)

      11. ICAAC: The PRESCO study: role of extended therapy and/or optimal doses of ribavirin in the treatment of chronic hepatitis C in HIV-infected patients (12/12/06)

      12. Fatty Liver Associated with Increased Mortality - (12/12/06)

      13. Pegasys/RBV Reverses Fibrosis in HCV/HIV-Coinfected in APRICOT Study for Viral Responders, Non-responders, and Cirrhosis - (12/12/06)

      14. HCV Reduces Cholesterol in Coinfected; Interferon therapy Increases Cholesterol - (12/12/06)

      15. Diabetes and hepatocellular carcinoma Editorial - (12/12/06)

      16. Abbott Acquires HCV Protease Inhibitors from Enanta Pharma - (12/12/06)

      17. Valeant Pharmaceuticals Initiates Infergen Phase 4 Study - (12/12/06)

      18. Hepatitis C Virus Replicates in the Liver of Patients Who Have a Sustained Response to Antiviral Treatment - (12/06/06)

      19. Hepatitis C Virus Seropositivity in Organ Donors Reduced Survival in Heart Transplant Recipients - (12/06/06)

      20. Poorer Outcomes for Recipients of Heart Allografts From HCV-Positive Donors EDITORIAL - (12/06/06)






      --------------------------------------------------------------------------------


      _______________________________________________
      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

      _______________________________________________



      --------------------------------------------------------------------------------


      No virus found in this incoming message.
      Checked by AVG Free Edition.
      Version: 7.5.432 / Virus Database: 268.15.26/594 - Release Date: 12/20/2006 3:54 PM


      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.